AI Drug Discovery
AI is transforming drug discovery, cutting timelines by years. But the law is struggling to keep up—understanding the IP landscape is critical for protecting your innovations.
Award-Winning Research
Recognized for "Emerging Legal Terrain: IP Risks from AI's Role in Drug Discovery" — one of only 20 articles selected from the nation's 1,000 largest law firms.
Key Legal Considerations
Patent protection requires significant human contribution to the invention—AI cannot be listed as an inventor under current law (Thaler v. Vidal).
Small molecules carry lower IP risk than antibodies/polypeptides because synthesis is unpredictable, requiring human contribution to reduction to practice.
Proper documentation of human contributions vs. AI involvement is essential for patent applications and M&A due diligence.
Different Perspectives
Related Articles
Exploring the legal implications of AI-driven drug discovery, including patent eligibility, inventorship challenges, and strategies for pharmaceutical companies to protect their innovations.
Key mistakes life sciences companies make when developing AI governance frameworks, from patent inventorship complexities to inadequate documentation standards.
Understanding how patenting drugs discovered with AI assistance requires significant human contribution, and strategies for startups and big pharma to navigate these challenges.
Diving into the Thaler v. Vidal decision and what it means for the future of life sciences and technology patents when AI assists in innovation.
Exploring considerations for companies large and small innovating in AI drug discovery, including ensuring human contribution and assessing third-party AI tools.
Comprehensive guide on IP risks, licensing considerations, M&A due diligence, and documentation practices for companies using AI in drug discovery.
I help pharmaceutical companies and biotech startups develop IP strategies that protect AI-assisted discoveries while positioning for successful exits and partnerships.
Get in Touch